Brazil has taken a new step towards strengthening its healthcare system and advancing cancer treatment after President Luiz Inacio Lula da Silva signed into law a new regulatory framework governing the development and access to cancer vaccines and high-cost oncology medicines.
The legislation establishes comprehensive guidelines for the research, production, distribution and equitable provision of innovative cancer therapies within the country’s public health system. The framework prioritises scientific innovation, universal access and international collaboration, reinforcing the role of Brazil’s Unified Health System (SUS) in delivering advanced medical care to all citizens.
According to Agência Brasil, the newly adopted law aims to foster domestic research and manufacturing capabilities while ensuring that cutting-edge cancer treatments become accessible to patients across the country. By establishing a clear regulatory pathway, the framework is expected to accelerate the development of therapeutic vaccines and support partnerships with international research institutions.
The Ministry of Health announced an investment package of approximately US$20 million to support the development of the new centre and related healthcare initiatives. Funding will also facilitate the establishment of a telehealth nucleus, enabling the specialisation of medical professionals in fields such as obstetrics and cardiology and expanding access to expert care across Brazil.
Furthermore, plans were unveiled to develop the country’s first fully “intelligent” public hospital, integrating artificial intelligence, 5G-connected ambulances and telehealth technologies. The initiative aims to significantly reduce emergency response times and improve outcomes for critically ill patients.